Cedar Mountain Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15K Hold
105
– – ﹤0.01% 365
2026
Q2
$16.5K Buy
105
+19
+22% +$2.85K ﹤0.01% 384
2026
Q1
$13.1K Sell
86
-53
-38% -$8.12K ﹤0.01% 389
2025
Q4
$19.2K Sell
139
-3
-2% -$393 ﹤0.01% 186
2025
Q3
$18.2K Buy
+142
New +$17.3K ﹤0.01% 195
2023
Q3
– Sell
-70
Closed -$7.06K – 320
2023
Q2
$7.06K Sell
70
-9
-11% -$900 ﹤0.01% 187
2023
Q1
$7.27K Buy
+79
New +$6.9K ﹤0.01% 186
2020
Q1
– Sell
-302
Closed -$29K – 261
2019
Q4
$29K Buy
+302
New +$27.1K 0.01% 86

Other funds holding NVS

Cedar Mountain Advisors's NVS Position: Q3 2026 in Review

Cedar Mountain Advisors held its Novartis (NVS) position steady in Q3 2026 at 105 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Cedar Mountain Advisors first reported a position in NVS in Q4 2019 and has held it in 8 quarters since. The position peaked at $29K in Q4 2019. 1,535 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Cedar Mountain Advisors held 105 shares of Novartis worth $15K as of Q3 2026.
  • Cedar Mountain Advisors left its Novartis share count unchanged in Q3 2026.
  • Novartis made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #365 holding.
  • Cedar Mountain Advisors first reported a position in Novartis in Q4 2019 and has held it in 8 quarters since.
  • Cedar Mountain Advisors's Novartis position peaked at $29K in Q4 2019.
  • 1,535 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.